Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Non-infectious anterior uveitis~* Grade 1 - Grade 3 anterior chamber cell count~* Subjects must have Intraocular pressure \<25 mmHg at baseline and may only administer a maximum of 1 topical medication to control Intraocular pressure in the study eye.~* Visual acuity ≥ 20/200 in the study eye~Exclusion Criteria:~* Severe/serious ocular pathology~* Active intermediate or posterior uveitis.~* Previous anterior uveitis episode in the study eye within 4 weeks of Visit 1~* Oral corticosteroids within 14 days of Visit 1~* Intravitreal or sub-Tenon corticosteroid treatment in the study eye within the past 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NS2 (Type: EXPERIMENTAL): NS2 ophthalmic drops (0.5%) in the affected eye
- NS2 and Pred Forte (Type: EXPERIMENTAL): NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
- Pred Forte (Type: ACTIVE_COMPARATOR): Prednisolone acetate ophthalmic suspension (1%) in the affected eye

Based on this trial design, predict the completion outcome and termination type (if applicable).